Samantha Fleischman
Payments from drug & device makers
Across 76 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$576
- EMD Serono, Inc.$182
- AbbVie$163
- Johnson & Johnson$155
- Gilead$154
- Takeda Pharmaceuticals U.S.A., Inc.$96
- plus $497 from 13 others
What the payments were for
- Food & beverage$1,823100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 24 | $576 |
| EMD Serono, Inc. | 9 | $182 |
| AbbVie | 6 | $163 |
| Johnson & Johnson | 6 | $155 |
| Gilead | 5 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| Merck | 3 | $74 |
| Lilly USA, LLC | 3 | $71 |
| Theratechnologies Inc. | 2 | $69 |
| Lundbeck LLC | 2 | $49 |
| Idorsia Pharmaceuticals US Inc | 2 | $48 |
| Novo Nordisk | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Braeburn Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $23 |
| GSK | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$1,823 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $48,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $154 | $48,02212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.
Other family in Nyack
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.